查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1618780

癌症药物市场：按适应症、药物类别、给药途径、分销和最终用途 - 2025-2030 年全球预测

Oncology Drugs Market by Indication (Bladder Cancer, Breast Cancer, Cervical Cancer), Drug Class (Chemotherapy, Hormonal Therapy, Immunotherapy), Route of Administration, Distribution, End-use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年癌症治疗市值为1757.8亿美元，预计到2024年将达到1884.1亿美元，复合年增长率为7.64%，到2030年将达到2944.2亿美元。

癌症治疗市场是根据不同癌症的治疗范围来定义的，包括化疗、免疫疗法、标靶治疗和荷尔蒙疗法等多种治疗方法。全球癌症发生率的上升凸显了对癌症药物的需求，推动了对改善患者生存和生活品质的创新治疗的需求。这些药物具有广泛的用途，包括医院、癌症研究中心和专科诊所，最终用途为儿科、成人和老年患者。影响该市场的主要成长要素包括生物技术的进步、癌症研究资金的增加以及新疗法的不断增加。此外，随着世界各地监管机构强调药物核准速度，个人化医疗和生物相似药的开发潜力带来了利润丰厚的机会。为了利用这些机会，企业应专注于投资研发，促进与研究机构的合作，并开拓医疗需求未被满足的新兴市场。然而，市场成长面临的挑战包括治疗成本上升、严格的法律规范以及治疗方法的潜在副作用，这些可能会阻碍患者的取得和负担能力。此外，因地区而异的复杂报销情况也导致了进一步的延误。创新应优先考虑精准肿瘤学，即根据基因图谱客製化治疗方法，并探索整合不同治疗方法以获得卓越疗效的联合治疗。总体而言，市场动态是一个动态市场，其特征是技术快速发展和高度竞争。公司必须保持敏捷，不断适应科学进步和政策变化，以保持竞争力。对人工智慧和机器学习等数位健康技术的策略性投资可以进一步改善药物开发流程和患者治疗结果，最终推动这个强劲行业的业务成长。

主要市场统计
基准年[2023] 1757.8亿美元
预计年份 [2024] 1884.1亿美元
预测年份 [2030] 2944.2亿美元
复合年增长率（%） 7.64%

市场动态：揭示快速发展的癌症药物市场的关键市场洞察

供需的动态交互作用正在改变癌症药物市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球癌症盛行率迅速上升
    • 增加抗癌药物开发的投资和政府资助
    • 扩大个人化医疗的研究与开发
  • 市场限制因素
    • 精准医学治疗相关的高成本
  • 市场机会
    • 基因组定序技术和生物技术的进展
    • 利用生物标记进行药物开发的进展
  • 市场挑战
    • 严格的监管要求和药物开发的复杂性

波特五力：驾驭癌症药物市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对癌症药物市场的影响

外部宏观环境因素在塑造癌症治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解癌症治疗药物市场的竞争状况

对癌症治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵癌症治疗市场供应商的绩效评估

FPNV定位矩阵是评估癌症治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议 绘製癌症治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，癌症药物市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球癌症发生率正在迅速增加
      • 增加对癌症药物开发的投资和政府资助
      • 扩大个人化医疗的研究与开发
    • 抑制因素
      • 精准医学治疗相关的高成本
    • 机会
      • 基因组序列分析技术和生物技术的进展
      • 生物标誌物主导的药物开发
    • 任务
      • 严格的监管要求和药物开发的复杂性
  • 市场区隔分析
    • 药物类别：由于准确性和副作用较少，标靶治疗变得越来越重要
    • 最终用途：癌症诊所的持续扩张加速了癌症药物的需求
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依适应症分類的癌症治疗药物市场

  • 膀胱癌
  • 乳癌
  • 子宫颈癌
  • 大肠直肠癌
  • 食道癌
  • 肾癌
  • 肝癌
  • 肺癌
  • 摄护腺癌
  • 胃癌

第七章按药物类别分類的癌症药物市场

  • 化疗
  • 荷尔蒙疗法
  • 免疫疗法
  • 标靶治疗

第八章癌症药物市场：依给药途径分类

  • 静脉
  • 口服
  • 话题

第九章 癌症治疗药物市场经销商

  • 线下药局
    • 医院药房
    • 零售药房
  • 网路药房

第十章癌症药物市场：依最终用途分类

  • 家庭保健
  • 医院
  • 癌症专科诊所

第11章：美洲的癌症药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章 亚太地区抗癌药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲的癌症药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • FDA核准XTANDI 用于高风险前列腺癌治疗
    • 武田製药的 FRUZAQLA 获得 FDA核准用于治疗转移性大肠癌
    • FDA核准武田的 FRUZAQLA，一种治疗转移性大肠直肠癌的新疗法
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Agenus Inc.
  • Amgen Inc.
  • Aspen Pharmacare Holdings Limited
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Debiopharm International SA
  • Eli Lilly and Company
  • EMD Serono, Inc. by Merck KGaA
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Pfizer Inc.
  • Puma Biotechnology, Inc.
  • Shorla Pharma Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Sutro Biopharma, Inc.
  • Takeda Pharmaceutical Company Limited
  • Viatris Inc.
Product Code: MRR-434CCDA05255

The Oncology Drugs Market was valued at USD 175.78 billion in 2023, expected to reach USD 188.41 billion in 2024, and is projected to grow at a CAGR of 7.64%, to USD 294.42 billion by 2030.

The oncology drugs market, defined by its scope of treatment for various cancers, encompasses a wide array of therapeutic modalities, including chemotherapy, immunotherapy, targeted therapy, and hormone therapy. The necessity of oncology drugs is underscored by the rising global cancer incidence, which drives demand for innovative treatments that improve patient survival and quality of life. The application of these drugs spans diverse settings such as hospitals, cancer research centers, and specialized clinics, with end-use extending to pediatric, adult, and geriatric patients. Key growth factors influencing this market include advancements in biotechnology, increased funding for cancer research, and a growing pipeline of novel therapeutics. Moreover, the potential of personalized medicine and the development of biosimilars present lucrative opportunities, with regulatory bodies worldwide emphasizing expedition in drug approvals. To leverage these opportunities, companies should focus on investing in R&D, fostering collaborations with research institutes, and exploring emerging markets with unmet medical needs. However, market growth is challenged by high treatment costs, stringent regulatory frameworks, and potential side effects of therapies, which can hinder patient access and affordability. Furthermore, complex reimbursement scenarios in different regions pose additional delays. Innovation should prioritize precision oncology, which tailors treatments based on genetic profiles, and explore combination therapies that integrate different therapeutic approaches for superior efficacy. Overall, the oncology drugs market is dynamic, characterized by rapid technological evolution and high competition. Companies must remain agile, continuously adapting to scientific advancements and policy changes to maintain their competitive edge. Strategic investments in digital health technologies, such as AI and machine learning, can further enhance drug development processes and patient outcomes, ultimately driving business growth in this robust sector.

KEY MARKET STATISTICS
Base Year [2023] USD 175.78 billion
Estimated Year [2024] USD 188.41 billion
Forecast Year [2030] USD 294.42 billion
CAGR (%) 7.64%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Oncology Drugs Market

The Oncology Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Surging prevalence of cancer across the globe
    • Increase in investments and government funding in development of cancer drugs
    • Growing research & development in personalized medicines
  • Market Restraints
    • High costs associated with the precision medicine therapies
  • Market Opportunities
    • Advancements in genomic sequencing technologies and biotechnology
    • Development of biomarker-driven drug development
  • Market Challenges
    • Stringent regulatory requirements and the complexity of drug development

Porter's Five Forces: A Strategic Tool for Navigating the Oncology Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Oncology Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Oncology Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Oncology Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Oncology Drugs Market

A detailed market share analysis in the Oncology Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Oncology Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Oncology Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Oncology Drugs Market

A strategic analysis of the Oncology Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Oncology Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Agenus Inc., Amgen Inc., Aspen Pharmacare Holdings Limited, Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, BeiGene, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Limited, Debiopharm International SA, Eli Lilly and Company, EMD Serono, Inc. by Merck KGaA, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Pfizer Inc., Puma Biotechnology, Inc., Shorla Pharma Ltd., Sun Pharmaceutical Industries Ltd., Sutro Biopharma, Inc., Takeda Pharmaceutical Company Limited, and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Oncology Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Indication, market is studied across Bladder Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Esophagus Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Prostate Cancer, and Stomach Cancer.
  • Based on Drug Class, market is studied across Chemotherapy, Hormonal Therapy, Immunotherapy, and Targeted Therapy.
  • Based on Route of Administration, market is studied across Intravenous, Oral, and Topical.
  • Based on Distribution, market is studied across Offline Pharmacies and Online Pharmacies. The Offline Pharmacies is further studied across Hospital Pharmacies and Retail Pharmacies.
  • Based on End-use, market is studied across Home Healthcare, Hospitals, and Specialty Cancer Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Surging prevalence of cancer across the globe
      • 5.1.1.2. Increase in investments and government funding in development of cancer drugs
      • 5.1.1.3. Growing research & development in personalized medicines
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with the precision medicine therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in genomic sequencing technologies and biotechnology
      • 5.1.3.2. Development of biomarker-driven drug development
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirements and the complexity of drug development
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: Growing significance of targeted therapy due to its precision and lower side effects
    • 5.2.2. End-use: Ongoing expansion of specialty cancer clinics accelerating the demand for oncology drugs
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Oncology Drugs Market, by Indication

  • 6.1. Introduction
  • 6.2. Bladder Cancer
  • 6.3. Breast Cancer
  • 6.4. Cervical Cancer
  • 6.5. Colorectal Cancer
  • 6.6. Esophagus Cancer
  • 6.7. Kidney Cancer
  • 6.8. Liver Cancer
  • 6.9. Lung Cancer
  • 6.10. Prostate Cancer
  • 6.11. Stomach Cancer

7. Oncology Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Chemotherapy
  • 7.3. Hormonal Therapy
  • 7.4. Immunotherapy
  • 7.5. Targeted Therapy

8. Oncology Drugs Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral
  • 8.4. Topical

9. Oncology Drugs Market, by Distribution

  • 9.1. Introduction
  • 9.2. Offline Pharmacies
    • 9.2.1. Hospital Pharmacies
    • 9.2.2. Retail Pharmacies
  • 9.3. Online Pharmacies

10. Oncology Drugs Market, by End-use

  • 10.1. Introduction
  • 10.2. Home Healthcare
  • 10.3. Hospitals
  • 10.4. Specialty Cancer Clinics

11. Americas Oncology Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Oncology Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Oncology Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. FDA Approves XTANDI for High-Risk Prostate Cancer Management
    • 14.3.2. Takeda's FRUZAQLA Receives FDA Approval for Metastatic Colorectal Cance
    • 14.3.3. FDA Approves Takeda's FRUZAQLA, a Novel Treatment for Metastatic Colorectal Cancer
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Agenus Inc.
  • 3. Amgen Inc.
  • 4. Aspen Pharmacare Holdings Limited
  • 5. Astellas Pharma Inc.
  • 6. AstraZeneca PLC
  • 7. Bayer AG
  • 8. BeiGene, Inc.
  • 9. Boehringer Ingelheim GmbH
  • 10. Bristol-Myers Squibb Company
  • 11. Cipla Limited
  • 12. Debiopharm International SA
  • 13. Eli Lilly and Company
  • 14. EMD Serono, Inc. by Merck KGaA
  • 15. F. Hoffmann-La Roche Ltd.
  • 16. GlaxoSmithKline PLC
  • 17. Johnson & Johnson Services, Inc.
  • 18. Pfizer Inc.
  • 19. Puma Biotechnology, Inc.
  • 20. Shorla Pharma Ltd.
  • 21. Sun Pharmaceutical Industries Ltd.
  • 22. Sutro Biopharma, Inc.
  • 23. Takeda Pharmaceutical Company Limited
  • 24. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. ONCOLOGY DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ONCOLOGY DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ONCOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ONCOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. ONCOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ONCOLOGY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ONCOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ONCOLOGY DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ESOPHAGUS CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY STOMACH CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SPECIALTY CANCER CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 86. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. CHINA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 92. CHINA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 93. CHINA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. INDIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 98. INDIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 99. INDIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 104. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 105. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 110. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 111. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 116. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 117. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 122. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 123. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 128. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 129. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 134. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 135. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 140. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 141. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 146. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 147. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 152. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 153. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 165. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 166. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 171. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 172. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 177. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 178. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 183. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 184. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. GERMANY ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 189. GERMANY ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 190. GERMANY ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 194. ISRAEL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 195. ISRAEL ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 196. ISRAEL ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 200. ITALY ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 201. ITALY ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 202. ITALY ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 206. NETHERLANDS ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 207. NETHERLANDS ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 208. NETHERLANDS ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 212. NIGERIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 213. NIGERIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 214. NIGERIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 218. NORWAY ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 219. NORWAY ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 220. NORWAY ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 224. POLAND ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 225. POLAND ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 226. POLAND ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 230. QATAR ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 231. QATAR ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 232. QATAR ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 236. RUSSIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 237. RUSSIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 238. RUSSIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 242. SAUDI ARABIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 243. SAUDI ARABIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 244. SAUDI ARABIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH AFRICA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 249. SOUTH AFRICA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 250. SOUTH AFRICA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 254. SPAIN ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 255. SPAIN ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 256. SPAIN ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 260. SWEDEN ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 261. SWEDEN ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 262. SWEDEN ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 266. SWITZERLAND ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 267. SWITZERLAND ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 268. SWITZERLAND ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 272. TURKEY ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 273. TURKEY ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 274. TURKEY ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED ARAB EMIRATES ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED ARAB EMIRATES ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 284. UNITED KINGDOM ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 285. UNITED KINGDOM ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 286. UNITED KINGDOM ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 287. ONCOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 288. ONCOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023